Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (91-100 of 315) with videos related to

Pageof 32
Sort By:
Pharmacology & Therapeutics|February 9, 2017
Inhibitors of cyclin-dependent kinases as cancer therapeuticsSteven R Whittaker, Aurélie Mallinger, Paul Workman, et al.
Current Opinion in Pharmacology|June 29, 2015
Drugging PI3K in cancer: refining targets and therapeutic strategiesTimothy A Yap, Lynn Bjerke, Paul A Clarke, et al.
Molecular Cancer Therapeutics|April 1, 2008
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitorsUdai Banerji, Annette Affolter, Ian Judson, et al.
Cancer Research|February 19, 2008
Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycinJoanna L Holmes, Swee Y Sharp, Steve Hobbs, et al.
Nature Biotechnology|July 15, 2006
Drugging the PI3 kinomePaul Workman, Paul A Clarke, Sandrine Guillard, et al.
Cancer Research|January 4, 2019
Correction: Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-DemethoxygeldanamycinJoanna L Holmes, Swee Y Sharp, Steve Hobbs, et al.
Current Pharmaceutical Design|September 28, 2016
Polypharmacology in Precision Oncology: Current Applications and Future ProspectsAlbert A Antolin, Paul Workman, Jordi Mestres, et al.
Plos Computational Biology|December 25, 2015
Distinctive Behaviors of Druggable Proteins in Cellular NetworksCostas Mitsopoulos, Amanda C Schierz, Paul Workman, et al.
Cellular Signalling|January 14, 2018
Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signallingMichael D Bright, Paul A Clarke, Paul Workman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2016
Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug DevelopmentTimothy A Yap, Udai Banerji, Johann S de Bono, et al.
Pageof 32

Showing results (91-100 of 315) with videos related to

Sort By:
Pageof 32
Pharmacology & Therapeutics|February 9, 2017
Inhibitors of cyclin-dependent kinases as cancer therapeuticsSteven R Whittaker, Aurélie Mallinger, Paul Workman, et al.
Current Opinion in Pharmacology|June 29, 2015
Drugging PI3K in cancer: refining targets and therapeutic strategiesTimothy A Yap, Lynn Bjerke, Paul A Clarke, et al.
Molecular Cancer Therapeutics|April 1, 2008
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitorsUdai Banerji, Annette Affolter, Ian Judson, et al.
Cancer Research|February 19, 2008
Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycinJoanna L Holmes, Swee Y Sharp, Steve Hobbs, et al.
Nature Biotechnology|July 15, 2006
Drugging the PI3 kinomePaul Workman, Paul A Clarke, Sandrine Guillard, et al.
Cancer Research|January 4, 2019
Correction: Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-DemethoxygeldanamycinJoanna L Holmes, Swee Y Sharp, Steve Hobbs, et al.
Current Pharmaceutical Design|September 28, 2016
Polypharmacology in Precision Oncology: Current Applications and Future ProspectsAlbert A Antolin, Paul Workman, Jordi Mestres, et al.
Plos Computational Biology|December 25, 2015
Distinctive Behaviors of Druggable Proteins in Cellular NetworksCostas Mitsopoulos, Amanda C Schierz, Paul Workman, et al.
Cellular Signalling|January 14, 2018
Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signallingMichael D Bright, Paul A Clarke, Paul Workman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2016
Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug DevelopmentTimothy A Yap, Udai Banerji, Johann S de Bono, et al.
Pageof 32